entertainment -WSS

entertainment

author：leisure time 2025-10-01 23:06:22 - browse：99

An ALS patient receives support. -- health coverage from STAT — Adobe

Years of polarizing scientific discourse and bruising online debate will come to a head next week when advisers to the Food and Drug Administration weigh in on NurOwn, a potential treatment to slow the progression of ALS that has bitterly divided physicians and patient advocates.

On Sept. 27, a panel of experts will consider the convoluted data supporting the potential approval of NurOwn, a stem-cell therapy the FDA previously refused to even consider. To some physicians, the drug’s failure to show significant benefits in clinical studies leaves approval out of the question. Others, including the influential ALS Association, say NurOwn’s manufacturer, a small biotech firm called BrainStorm Cell Therapeutics, hasn’t disclosed enough information to properly determine the medicine’s value.

Another group of patients and doctors argue that NurOwn’s supporting evidence, while problematic, justifies making it available to the roughly 30,000 ALS patients in the U.S., people for whom there is currently no hope of arresting an incurable disease that gradually erodes motor function and leads to death within about five years of diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Behind warning on Apellis’s eye drug lies a conflict of interest

WSS

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Biden jokes that Republicans may impeach him because inflation is starting to cool down

VC firm RA Capital starts a new synthetic biology incubator

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

hotspot

entertainment

hotspot

Medical records are filled with copy

Europe sees delivery challenges ahead on Alzheimer's therapies

United colonoscopy coverage change 'may cost lives,' doctors say

Can CDC director Mandy Cohen drive consensus in Washington?

DIEP, the 'gold standard' of breast reconstruction, is under threat

VC firm RA Capital starts a new synthetic biology incubator

23andMe had bad news about my health. I wish a person had delivered it

Alexander Hamilton and the argument for universal insurance

Supreme Court strikes down use of affirmative action

Europe sees delivery challenges ahead on Alzheimer's therapies

leisure time

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

Federal judge rules Oregon’s tough new gun law is constitutional

Who gets to use the title 'doctor'?

Public health communication lessons from Covid

Can CDC director Mandy Cohen drive consensus in Washington?

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

knowledge

explore

hotspot

explore